Skip to contentN
Niagen Bioscience, Inc.
N
NAGENiagen Bioscience, Inc. Q1 2015 · 10-Q
Revenue$5.26M$5.26M+71.1% vs Q1 2014 Net Income-$1.03M-$1.03MN/M vs Q1 2014 EPS Diluted-$0.03-$0.03N/M vs Q1 2014 Gross Profit$1,927,624+95.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Niagen Bioscience, Inc. · CIK 1386570 · Engraved from SEC EDGAR
Operating Cash Flow-$591,058N/M Free Cash Flowderived-$686,836N/M Margins · derivedGross margin36.6%+4.6 pt vs Q1 2014
Operating margin-17.2%+42.6 pt vs Q1 2014
Net margin-19.5%+40.6 pt vs Q1 2014
ended Apr 4, 2015 · filed May 14, 2015 · 40 d after period end